日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2.

优化人源单克隆抗体以更好地中和 SARS-CoV-2

期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-61472-z
Wang Qian, Guo Yicheng, Casner Ryan G, Yu Jian, Nair Manoj S, Ho Jerren, Reddem Eswar R, Mellis Ian A, Wu Madeline, Tzang Chih-Chen, Hong Hsiang, Huang Yaoxing, Shapiro Lawrence, Liu Lihong, Ho David D
炎症/感染
新冠
Human
发表日期：2025
文献求助 收藏

Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages

研究级 Pemivibart 对近期 SARS-CoV-2 JN.1 亚系的活性

期刊:New England Journal of Medicine
影响因子:78.5
doi:10.1056/NEJMc2410203
Wang, Qian; Guo, Yicheng; Ho, Jerren; Ho, David D
SARS-CoV-2
发表日期：2024
文献求助 收藏

Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages

SARS-CoV-2 刺突蛋白的反复突变赋予特定 JN.1 亚系生长优势

期刊:Emerging Microbes & Infections
影响因子:7.5
doi:10.1080/22221751.2024.2402880
Wang, Qian; Mellis, Ian A; Ho, Jerren; Bowen, Anthony; Kowalski-Dobson, Theresa; Valdez, Riccardo; Katsamba, Phinikoula S; Wu, Madeline; Lee, Caitlin; Shapiro, Lawrence; Gordon, Aubree; Guo, Yicheng; Ho, David D; Liu, Lihong
SARS-CoV-2
发表日期：2024
文献求助 收藏

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation

SARS-CoV-2 omicron 亚型 BA.4.6 对抗体中和的抵抗力

期刊:Lancet Infectious Diseases
影响因子:31
doi:10.1016/S1473-3099(22)00694-6
Wang, Qian; Li, Zhiteng; Ho, Jerren; Guo, Yicheng; Yeh, Andre Yanchen; Mohri, Hiroshi; Liu, Michael; Wang, Maple; Yu, Jian; Shah, Jayesh G; Chang, Jennifer Y; Herbas, Favio; Yin, Michael T; Sobieszczyk, Magdalena E; Sheng, Zizhang; Liu, Lihong; Ho, David D
SARS-CoV-2
发表日期：2022
文献求助 收藏